Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTI-1066 in Advanced Solid Tumors
NCT03398720Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR-A1403 in solid tumor (4 cohorts), sponsored by Hengrui. Primary endpoints: Adverse events up to 2 years and Dose-limiting toxicity up to 2 years. Status: unknown.
02
Drugs
SHR-A1403
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03398720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398720.